在癌症免疫治疗后,PPP2R1A突变预示着更好的存活率
Yibo Dai1,2, Anne Knisely3, Mitsutake Yano4
1Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nature
|July 3, 2025
概括
在接受免疫检查点阻塞 (ICB) 治疗的患者中,PPP2R1A突变可能预测更好的结果. 针对PPP2R1A可以在各种免疫疗法中提高存活率.
科学领域:
- 癌症学
- 免疫学
- 癌症遗传学
背景情况:
- 免疫检查点阻断 (ICB) 疗法在癌症治疗中表现有前途,但在抵抗方面面临挑战.
- 卵巢透明细胞癌是一种具有挑战性的癌症,治疗选择有限.
- 确定生物标志物和新的治疗点对于提高ICB疗效至关重要.
研究的目的:
- 研究PPP2R1A突变对ICB治疗的反应作用.
- 在各种癌症中探索针对PPP2R1A的免疫微环境和临床前疗效.
- 确定PPP2R1A是否是增强免疫治疗结果的潜在治疗标.
主要方法:
- 用ICB治疗的卵巢清细胞癌和其他癌症类型的患者队列的分析.
- 对免疫细胞透,信号通路 (IFNγ) 和三级淋巴体结构进行瘤活检分析.
- 使用体外和体内模型进行临床前研究,以评估PPP2R1A向 (药理/遗传) 对免疫治疗反应的影响.
- 评估与PPP2R1A突变状态和免疫治疗方案相关的生存结果.
主要成果:
- 患有PPP2R1A突变瘤的患者在ICB治疗后的总生存时间和无进展生存时间显著延长.
- 这些发现在多种癌症类型和ICB治疗患者群体中得到了验证.
- 在PPP2R1A突变的瘤中,IFNγ信号增强,基线三级淋巴细胞结构增加,ICB后CD45RO+CD8+T细胞透增加.
- 在临床前模型中向PPP2R1A改善了ICB和CAR- T细胞治疗的存活率.
结论:
- PPP2R1A突变与ICB治疗的改善反应有关.
- 向PPP2R1A是提高ICB和其他免疫疗法的潜在策略.
- 需要进一步研究以充分阐明针对PPP2R1A的机制和治疗潜力.
相关概念视频
Tumor Immunotherapy
667
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
667
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


